Showing results (91-100 of 178) with videos related to
Sort By:
Pageof 18
Cancer Research|April 19, 2011
Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptorsPierre Zindy, Yann Bergé, Ben Allal, et al.The Oncologist|August 19, 2023
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal CancerEric Van Cutsem, Rona Yaeger, Jean-Pierre Delord, et al.European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 studyCaroline Even, Jean-Pierre Delord, Katharine A Price, et al.Science Immunology|June 8, 2023
Distant antimetastatic effect of enterotropic colon cancer-derived α4β7Virginie Feliu, Carlos Gomez-Roca, Marie Michelas, et al.Frontiers in Immunology|August 13, 2024
Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation and predict resistance to immune checkpoint inhibitors in advanced melanoma patientsCarine Dufau, Matthieu Genais, Elodie Mucher, et al.JHEP Reports : Innovation in Hepatology|April 15, 2024
A phase Ib/II trial of capmatinib plus spartalizumab <i>vs.</i> spartalizumab alone in patients with pretreated hepatocellular carcinomaArmando Santoro, Eric Assenat, Thomas Yau, et al.Clinical Chemistry|August 8, 2019
Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective StudyRenaud Garrel, Martine Mazel, Françoise Perriard, et al.Journal of Molecular Cell Biology|September 11, 2019
Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factorsAugustin Le Naour, Mélissa Prat, Benoît Thibault, et al.Oncotarget|April 29, 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trialEric Assenat, David Azria, Caroline Mollevi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2015
CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer PatientsFabian Birzele, Edgar Voss, Adam Nopora, et al.Pageof 18